thursday 21 june 2012
hotel intercontinental, london
Contact
The event organiser is Ford Sinclair Ltd.
Please contact Jo Thomas or Julia Peachey.
T: 01277 350 557
E: jo.thomas@ford-sinclair.co.uk
julia.peachey@ford-sinclair.co.uk
voting panel
Mark CourtBuchanan At Buchanan, Mark advises a wide range of healthcare clients on their communication requirements. He joined Buchanan in 2003 after a successful career in journalism on titles including The Times, where he was Health Industries Correspondent, the Sunday Telegraph, Daily Mail and Investors Chronicle. A science graduate of London university, Mark also holds a diploma from the London College of Communication.
|
Glyn EdwardsSummit plc Glyn Edwards is CEO of Summit plc, Director of Oxford Cancer Biomarkers Limited and the National Cancer Research Institute and the interim Chief Executive Officer of the BioIndustry Association ('BIA'), a role from which he will step down from shortly. He was previously Chief Executive Officer of Antisoma from 1998-2011 and prior to this he worked in a variety of business development roles in the biotech and healthcare industries. Mr Edwards has a BSc in Biochemistry from Bristol University and an MSc in Economics from the London Business School. Glyn was made a Member of the British Empire as recognition for his services to the biotechnology industry.
|
Mary Jane ElliottM:Communications Mary-Jane leads the Healthcare team at M:Communications. She has more than 13 years of healthcare sector experience. Prior to joining M: Mary-Jane was a Partner at Buchanan Communications where she spent six years advising healthcare clients. Previously Mary-Jane worked at the FTSE 250 company PowderJect Pharmaceuticals where she began her career as a scientist and then joined the Corporate Communications and Investor Relations team. She has advised both public and private companies in the UK and internationally, across all sub-sectors of healthcare, and has a broad range of experience including work on various M&A situations, over 20 international IPOs and over 10 secondary fundraisings. As a healthcare specialist, Mary-Jane has a BSc (Hons) in BioMedical Sciences.
|
Stefan HamillPeel Hunt Stefan joined Peel Hunt in January 2011, joining forces with Paul Cuddon to form what we believe is the strongest team in UK healthcare and life sciences. Prior to joining Peel Hunt, Stefan was a founder of independent research house Clear Capital (now part of Espirito Santo) where he covered a wide variety of firms across the sector and was ranked number 3 in Extel. Stefan was formerly a strategy consultant and has a PhD in antibody engineering from the University of Cambridge.
|
Anthony HartleyMorgan Stanley Dr Anthony Hartley is an Executive Director in the Healthcare Investment Banking Group at Morgan Stanley, where he focuses on pharmaceutical and biotechnology companies on a pan-European basis. Anthony has spent over 10 years in healthcare investment banking, predominantly focused on the European biotech and pharmaceutical sectors, and has completed and advised on numerous M&A and corporate finance transactions in both the public and private biotech sectors. Before joining Morgan Stanley, Anthony previously worked for Lehman Brothers Europe and Credit Suisse First Boston. Anthony holds a Doctorate (D.Phil) in Pharmacology from The University of Oxford, and an MBA (Distinction) from Manchester Business School. Prior to his career in investment banking, Anthony spent a total of 7 years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GlaxoSmithkline and AstraZeneca. |
Oscar IzeboudKempen & Co Oscar joined Kempen & Co, a merchant bank based in Amsterdam the Netherlands, in 2006. He is currently Managing Director Corporate Finance, heading the Life Sciences/Healthcare team. Prior to this Oscar worked as Director Equity Research, covering European listed life sciences companies at Kempen & Co. Oscar has advised on a wide variety of primary and secondary public offerings and M&A transactions across Europe. Before Kempen & Co he worked in various commercial roles in the industry, eventually in business development at Crucell. Oscar obtained his PhD in Pharmacology at TNO in the Netherlands and he holds a MSc degree in Biopharmaceutical Sciences from the University of Leiden. |
Michael KingNomura Code Securities Michael joined Nomura Code Securities in 2003 from WestLB Panmure, having moved from SG Securities in 2000. He has over 13 years experience as a healthcare analyst and specialises in medical technology companies, although previously his coverage has also included the biotechnology and pharmaceutical sectors. Prior to joining SG Securities in 1997, Michael spent 12 years working in the medical technology industry, working for Amersham International (now GE Healthcare) and Pfizer Hospital Products, initially as a development scientist but mostly in international marketing. He graduated in 1985 with a degree in Biochemistry and Physiology from Southampton University. |
Geraldine O'KeeffeLife Sciences Partners Geraldine O'Keeffe, Partner, joined LSP as a Senior Investment Manager in 2008. Prior to joining LSP, she held the position of senior sell-side analyst at Fortis, where she focused exclusively on the global biotechnology industry. While at Fortis, she initiated and maintained coverage on a wide range of biotechnology companies and was actively involved in several IPOs. Before joining the investment community, Geraldine worked for Biotrin (now part of Diasorin) and was instrumental in gaining FDA approval for several diagnostic tests. She also lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a BSc Biochemistry/Microbiology from University College Cork, an MSc in Biotechnology from University College Galway, Ireland and conducted post-graduate research at the Max Planck Institute for Biophysical Chemistry and Oxford University. She is also a graduate of The Dublin School of Business. |
Gareth PowellPolar Capital Technology Trust PLC Gareth joined Polar Capital in 2007 to set up the healthcare team. He has over 12 years' investment experience in the healthcare sector, with 10 years as a Portfolio Manager. He joined Framlington in 1999 becoming a portfolio manager on the Framlington Health fund. In 2002, he helped launch and then run the Framlington Biotech Fund. Gareth became a CFA charter holder in 2003. Gareth studied biochemistry at Oxford from 1995 to 1999 and during that time worked at Astellas, the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and the Oxford Business School. |
Ian RestallFlathill Communications plc Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area, and since founding The Design Portfolio Marketing Services in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also President of The Design Portfolio Marketing Services Inc. and a member of the Investor Relations Society. |
Nick RodgersIPSO Ventures plc Nick is the CEO of technology commercialization business IPSO Ventures and the founder of the Mediscience Awards dinner. Nick is an accountant and former investment banker with Beeson Gregory (later Evolution Securities). Nick is also the Chairman of Oxford BioMedica plc and a Non-executive Director of TMO Renewables Limited and Morvus Technology Limited. |
Jonathan SeniorNomura Code Securities Jonathan joined Nomura Code in 2007. Previously, Jonathan was part of the healthcare corporate finance team at Credit Suisse and then a research analyst on the number one ranked biotech team. During his time at Credit Suisse, Jonathan was involved with the IPOs of NicOx, GPC Biotech and Actelion, as well as transactions for PowderJect, Oxford GlycoSciences and Galen. After leaving Credit Suisse, Jonathan joined Evolution Securities as a research analyst, where he was involved in fund raisings for Oxford BioMedica and Entelos. Prior to joining Credit Suisse, Jonathan was a doctor, with his final job before leaving medicine as a senior house officer in cardiac surgery at the John Radcliffe hospital in Oxford. Jonathan studied medicine at Lincoln College, Oxford and also holds a BA in Physiological Sciences. |
Melanie Toyne-SewellCollege Hill Life Sciences Melanie is a specialist in financial and corporate communications for Life Science companies, and heads up Financial PR for the Life Sciences team. Prior to College Hill, Melanie was Head of Healthcare at the Hogarth Partnership, a partner in the Financial Dynamics Life Sciences team and a Director of Merlin Financial. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare sectors. Before entering the field of financial PR, Melanie was at Price Waterhouse where she qualified as a chartered accountant. She has a BA Hons in Biochemistry from Oxford University. |
|
|
|
related content
The awards
Click here to see the list of awards at the European Mediscience Awards 2012
Shortlist
Shortlist tbc
Voting panel
Sign up for e-mail alerts
Event sponsored by
Nomura Code
Award sponsors
Buchanan
College Hill
Design Portfolio Marketing Services
Kempen & Co.
M:Communications
Peel Hunt
Guillain-Barre develops as an autoimmune reaction following an acute infection. This is a highly dangerous and little known problem so any funding and publicity helps immensely. The Support Group relies entirely on voluntary contributions.
GBS is a severe and potentially fatal condition in which the body's immune system attacks the myelin sheath surrounding peripheral nerves. This may result in weakness and even complete paralysis including of the muscles for breathing and swallowing. There is a need for research to help us to understand the causes of GBS and the mechanisms of damage, to find therapies to speed up recovery and to support those left with long-term disability.
www.gbs.org.uk